Literature DB >> 10807904

The tumor necrosis factor-related apoptosis-inducing ligand receptors TRAIL-R1 and TRAIL-R2 have distinct cross-linking requirements for initiation of apoptosis and are non-redundant in JNK activation.

F Mühlenbeck1, P Schneider, J L Bodmer, R Schwenzer, A Hauser, G Schubert, P Scheurich, D Moosmayer, J Tschopp, H Wajant.   

Abstract

Overexpression of the tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptors, TRAIL-R1 and TRAIL-R2, induces apoptosis and activation of NF-kappaB in cultured cells. In this study, we have demonstrated differential signaling capacities by both receptors using either epitope-tagged soluble TRAIL (sTRAIL) or sTRAIL that was cross-linked with a monoclonal antibody. Interestingly, sTRAIL was sufficient for induction of apoptosis only in cell lines that were killed by agonistic TRAIL-R1- and TRAIL-R2-specific IgG preparations. Moreover, in these cell lines interleukin-6 secretion and NF-kappaB activation were induced by cross-linked or non-cross-linked anti-TRAIL, as well as by both receptor-specific IgGs. However, cross-linking of sTRAIL was required for induction of apoptosis in cell lines that only responded to the agonistic anti-TRAIL-R2-IgG. Interestingly, activation of c-Jun N-terminal kinase (JNK) was only observed in response to either cross-linked sTRAIL or anti-TRAIL-R2-IgG even in cell lines where both receptors were capable of signaling apoptosis and NF-kappaB activation. Taken together, our data suggest that TRAIL-R1 responds to either cross-linked or non-cross-linked sTRAIL which signals NF-kappaB activation and apoptosis, whereas TRAIL-R2 signals NF-kappaB activation, apoptosis, and JNK activation only in response to cross-linked TRAIL.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10807904     DOI: 10.1074/jbc.M000482200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  38 in total

1.  NF-kappaB inducers upregulate cFLIP, a cycloheximide-sensitive inhibitor of death receptor signaling.

Authors:  S Kreuz; D Siegmund; P Scheurich; H Wajant
Journal:  Mol Cell Biol       Date:  2001-06       Impact factor: 4.272

2.  Selective targeting of death receptor 5 circumvents resistance of MG-63 osteosarcoma cells to TRAIL-induced apoptosis.

Authors:  Rachel M Locklin; Ermanno Federici; Belen Espina; Philippa A Hulley; R Graham G Russell; Claire M Edwards
Journal:  Mol Cancer Ther       Date:  2007-12-07       Impact factor: 6.261

3.  Designed tumor necrosis factor-related apoptosis-inducing ligand variants initiating apoptosis exclusively via the DR5 receptor.

Authors:  Almer M van der Sloot; Vicente Tur; Eva Szegezdi; Margaret M Mullally; Robbert H Cool; Afshin Samali; Luis Serrano; Wim J Quax
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-26       Impact factor: 11.205

4.  Death receptor 5 signaling promotes hepatocyte lipoapoptosis.

Authors:  Sophie C Cazanave; Justin L Mott; Steven F Bronk; Nathan W Werneburg; Christian D Fingas; X Wei Meng; Niklas Finnberg; Wafik S El-Deiry; Scott H Kaufmann; Gregory J Gores
Journal:  J Biol Chem       Date:  2011-09-22       Impact factor: 5.157

5.  NCTR25 fusion facilitates the formation of TRAIL polymers that selectively activate TRAIL receptors with higher potency and efficacy than TRAIL.

Authors:  Yan Wang; Qiong Lei; Cangjie Shen; Nan Wang
Journal:  Cancer Chemother Pharmacol       Date:  2021-05-04       Impact factor: 3.333

Review 6.  The Tumor Necrosis Factor Family: Family Conventions and Private Idiosyncrasies.

Authors:  David Wallach
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-10-01       Impact factor: 10.005

Review 7.  Exploring the TRAILs less travelled: TRAIL in cancer biology and therapy.

Authors:  Silvia von Karstedt; Antonella Montinaro; Henning Walczak
Journal:  Nat Rev Cancer       Date:  2017-05-24       Impact factor: 60.716

8.  Therapeutic effect of neural stem cells expressing TRAIL and bortezomib in mice with glioma xenografts.

Authors:  Irina V Balyasnikova; Sherise D Ferguson; Yu Han; Feifei Liu; Maciej S Lesniak
Journal:  Cancer Lett       Date:  2011-07-01       Impact factor: 8.679

Review 9.  The TRAIL to viral pathogenesis: the good, the bad and the ugly.

Authors:  Nathan Cummins; Andrew Badley
Journal:  Curr Mol Med       Date:  2009-05       Impact factor: 2.222

10.  The death ligand TRAIL in diabetic nephropathy.

Authors:  Corina Lorz; Alberto Benito-Martín; Anissa Boucherot; Alvaro C Ucero; Maria Pia Rastaldi; Anna Henger; Silvia Armelloni; Beatriz Santamaría; Celine C Berthier; Matthias Kretzler; Jesus Egido; Alberto Ortiz
Journal:  J Am Soc Nephrol       Date:  2008-02-20       Impact factor: 10.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.